Senti Bio Q2 net loss $11.2M; doses first patients in Phase 1 AML trial

Senti Biosciences, Inc.

2024-Q2 EPS reported -$5.10

Net loss of $11.2M ($2.45 per share) for Q2 2024; cash and equivalents $15.9M.
R&D expenses rose to $9.2M (vs $6.9M YoY) on increased manufacturing costs.
Phase 1 trial of SENTI-202 for AML now dosing; initial efficacy data expected by year-end 2024.
Received $8M CIRM grant to support SENTI-202 clinical development.
Regained Nasdaq minimum bid price compliance after 1-for-10 reverse stock split in July 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.